Abatacept. Clinical development;Abatacept. Desarrollo clínico

Reumatologia Clinica

Volumn 2, Issue SPEC. ISS. 2, 2006, Pages 35-37

  Martín Mola, Emilio ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; INFLIXIMAB; METHOTREXATE; PLACEBO;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33750856765     PISSN: 1699258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Harris JR, editor. Rheumatoid Arthritis. Filadelfia: WB Saunders Company; 1997.
2. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfield S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fussion protein CTLA4Ig. N Engl J Med. 2003;349:1907-15.
3. Disponible en: www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4170B1_02_01-FDA-Abatacept.pdf
4. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor á inhibition. N Engl J Med. 2005;353:1114-23.